skip to content

Wellcome-MRC Cambridge Stem Cell Institute


There are two platforms housed at the Cambridge Stem Cell Institute which support local and national activity in the biomedical application of pluripotent stem cells:

  • NIHR Cambridge Biomedical Centre (BRC) human Induced Pluripotent Stem Cells (hIPSC) core facility
  • UKRMP Pluripotent stem cells and engineered cells (PSEC).

hIPSC Core Facility

The NIHR Cambridge Biomedical Centre (BRC) hIPSCs core facility was created in 2009 to promote the clinical applications of human Induced Pluripotent Stem Cells (hIPSCs). The main activity of this platform is the production of hIPSC lines on demand for the development of in vitro models of disease, compatible with drug development and basic mechanistic studies. In addition, genome editing of hIPSCs for gene correction or for gene mutation is a growing activity for the BRC hIPSCs core facility. This platform also provides training to derive, grow and characterise hIPSC lines. Finally, the BRC hIPSC core facility is managing several research and development programs aiming to establish new methods of differentiation, inducible systems for gene targeting and more recently derivation of organoid from a diversity of organs including gut and liver.

During the past seven years, the BRC hIPSCs core facility has derived and characterised hIPSCs lines from 600 patients suffering from neurodegenerative diseases, cardiovascular syndromes, metabolic and blood disorders.  These projects have been directed by clinicians and basic scientists associated with different institutions in Europe and also with diverse BRC themes related to Neurosciences, Metabolic Science, Cardiovascular Medicine, Haematology, Surgery and Hepatology/Thoracic Medicine.

Located in Jeffrey Cheah Biomedical Centre, the BRC hIPSC core facility benefits from state of the art environment for stem cell research and also from the broad expertise of research groups of the Cambridge Stem Cell Institute. 


  • Ludovic Vallier, Director
  • Juned Kadiwala, Research Assistant
  • Ying Shao, Research Assistant 

UKRMP Pluripotent stem cells and engineered cells (PSEC)

Human pluripotent stem cells and regenerative medicine hold significant promise for a range of diseases, such as Parkinson's disease, liver disease and macular degeneration.

PSEC aims to advance regenerative medicine by overcoming the key outstanding hurdles to translate human Pluripotent Stem Cell (hPSC) based cellular therapies into standard clinical practice.

Using innovative, multidisciplinary approaches, the Hub aims to accelerate and streamline the process of translating hPSC-based therapies to the clinic and enabling their commercial development.


Research Team

  • Venkat Pisupati, Moyra Lawrence, Mercy Danga - University of Cambridge
  • Dylan Stavish, Duncan Baker - University of Sheffield
  • Preeti Holland - Loughborough University

UKRI Innovation/Rutherford Fellows aligned to UKRMP PSEC Hub: